RE:RE:RE:Photodynamic Therapy Market Size, Report 2022 to 2030Absolutely and yes I read everything that CancerSlayer posts as I have learned so much from him. My thought on commercialization is there is in my opinion a large percentage of patients will be not only unresponsive BCG but also those that are responsive for the simple fact of less treatments at a higher efficacy. Plus new NMIBC patients will seek Theralase's treatment over BCG.
As far as a $700 SP it will be a few years off unless there is a successful clinical trial with a high efficacy for Theralase's therapeutic/vaccine as both NMIBC & Therapeutic/Vaccine revenue will be in the billions.
Once they go into other indications I will post possible earnings calculations per share with various different factors .
As far as off label dosage and delivery method for other indications is beyond my comprehension and perhaps CancerSlayer or other knowledgeable people could tackle that one.